Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists

J Child Neurol. 2011 Jun;26(6):675-82. doi: 10.1177/0883073810395141. Epub 2011 Apr 25.


Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.

MeSH terms

  • Adolescent
  • Antibodies, Neutralizing / therapeutic use
  • Child
  • Consensus*
  • Delphi Technique
  • Demyelinating Autoimmune Diseases, CNS / diagnosis*
  • Demyelinating Autoimmune Diseases, CNS / epidemiology
  • Demyelinating Autoimmune Diseases, CNS / therapy*
  • Female
  • Humans
  • Injections, Intravenous / methods
  • Male
  • Methylprednisolone / administration & dosage
  • Physicians / standards*
  • Surveys and Questionnaires
  • United States


  • Antibodies, Neutralizing
  • Methylprednisolone